ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

通貨
46.81
買値
46.80
売値
46.84
出来高
109,609
45.47 日の範囲 47.07
37.02 52 週間の範囲 60.37
時価総額
前日終値
46.02
始値
46.07
最終取引時間
02:29:26
財務取引量
US$ 5,112,271
VWAP
46.641
平均取引量 (3 か月)
730,141
発行済株式数
92,344,268
配当利回り
-
PER
-7.15
1 株当たり利益 (EPS)
-6.57
歳入
434.25M
純利益
-606.64M

Ultragenyx Pharmaceutical Inc について

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Cr... Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
Ultragenyx Pharmaceutical Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker RARE. The last closing price for Ultragenyx Pharmaceutical was US$46.02. Over the last year, Ultragenyx Pharmaceutical shares have traded in a share price range of US$ 37.02 to US$ 60.37.

Ultragenyx Pharmaceutical currently has 92,344,268 shares in issue. The market capitalisation of Ultragenyx Pharmaceutical is US$4.25 billion. Ultragenyx Pharmaceutical has a price to earnings ratio (PE ratio) of -7.15.

RARE 最新ニュース

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit

Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 Phase 3 program on track to begin enrollment by...

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million Reaffirmed 2024 expected total revenue...

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

NOVATO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

NOVATO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.55-1.1613175675747.3648.1143.0482878345.04251496CS
4-7.85-14.361507500954.6655.443.0497247249.61060273CS
12-10.58-18.435267468257.3960.3743.0473014153.13322691CS
266.3515.694513099440.4660.3737.0279746948.24764365CS
527.5919.352371239239.2260.3737.0278079246.90868075CS
156-33.14-41.450906816879.9588.2231.5269234147.53500064CS
2608.5822.443107507238.23179.64731.5260931060.54813992CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
QMCOQuantum Corporation
US$ 7.6446
(90.16%)
20.73M
SKKSKK Holdings Limited
US$ 2.0354
(85.04%)
95.31M
INVZWInnoviz Technologies Ltd
US$ 0.08
(77.38%)
6.7k
PDYNPalladyne AI Corporation
US$ 3.1136
(55.68%)
38.3M
REPLReplimune Group Inc
US$ 15.96
(44.43%)
3.82M
AMIXAutonomix Medical Inc
US$ 6.10
(-54.88%)
638.54k
MSWMing Shing Group Holdings Ltd
 5.45
(-40.44%)
261.54k
CETXCemtrex Inc
US$ 0.1184
(-39.81%)
14.28M
APTOAptose Biosciences Inc
US$ 0.15491
(-36.51%)
8.42M
MTCMMTec Inc
US$ 0.21
(-31.77%)
39.15M
ELABElevai Labs Inc
US$ 0.0198
(-1.98%)
263.31M
VRPXVirpax Pharmaceuticals Inc
US$ 0.6271
(6.34%)
142.76M
NVDANVIDIA Corporation
US$ 142.12
(-3.10%)
129.96M
SMCISuper Micro Computer Inc
US$ 32.75
(10.27%)
102.2M
SKKSKK Holdings Limited
US$ 2.0354
(85.04%)
82.9M

RARE Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock